Discover more
than you think

Developing innovative treatments in immuno-oncology, CNS and rare diseases

About us

Proprietary
programs

We are advancing multiple first-in-class and best-in class programs.

Learn more

Partnered programs
Name Discovery Candidate Preclinical Clinical Partner
Adenosine A2AR antagonist Preclinical MERCK
Multi-target collaboration for CNS Discovery BOEHRINGER INGELHEIM
Multi-target collaboration for rare diseases Discovery PFIZER

Asset-centric
companies

Giving each program the best path forward

We create asset-centric vehicles for the development of our internal pipeline of preclinical candidates or to accelerate breakthrough innovations coming from academia. These asset-centric companies benefit from dedicated teams and targeted investments for a focused development.

Learn more

 

Discovery
engine

We build a strong pipeline using our drug discovery platforms to tackle brand new targets, challenging or orphan GPCRs considered intractable targets.

R&D
Technologies